| CME |
Report |
Total Revenue |
IN-LINE |
pred ~$1.705B vs. cons $1.71B |
MEDIUM |
| CME |
Report |
Adjusted EPS |
BEAT |
pred ~$3.02 vs. cons $2.98 |
MEDIUM |
| CME |
Report |
Average Daily Volume (ADV, contracts) |
MISS |
pred ~29.8M vs. cons ~30.5M |
MEDIUM |
| CME |
Guide |
FY2026 Adjusted Opex ex-license fees |
UNCHANGED |
guide ~$1.70B vs. cons $1.695B (FY2026) |
MEDIUM |
| CME |
Guide |
Market data revenue growth outlook |
LOWER |
guide ~13% vs. cons 14.6% (Q3 2026) |
LOW |
| CME |
Guide |
Rate-per-contract (RPC) trend |
LOWER |
guide ~$0.65 vs. cons $0.66 (Q3 2026) |
MEDIUM |
| CME |
Return |
Day-1 residual (stock − beta × S&P 500) |
+1.8% |
— |
MEDIUM |
| CME |
Return |
5-day cumulative residual |
+3.0% (FOLLOW-THROUGH) |
Bar was already lowered into the print (30-day downward EPS revisions, Zacks #4 Sell, tough Q2'25 comp), so an EPS beat plus documented May/June ADV reacceleration (33.2M and 30.6M records) gives sell-side (KBW, Redburn, Piper already bullish at ~$313-320 PT) ammunition to raise H2 volume/EPS estimates even as RPC mix compression and litigation overhang persist; oversold bounce (stock -28-30% off highs) plus new product catalysts (Single Stock Futures July 27) support continued drift higher over the week rather than a fade, though unresolved CFTC/perpetuals litigation caps upside and could truncate follow-through if commentary disappoints. |
MEDIUM |